Showing results (1311-1320 of 1,351) with videos related to
Sort By:
Pageof 136
Nature Communications|December 20, 2012
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitorsWenyu Yu, Emma J Chory, Amy K Wernimont, et al.International Journal of Biological Sciences|May 10, 2024
HMGA1 sensitizes esophageal squamous cell carcinoma to mTOR inhibitors through the ETS1-FKBP12 axisJin-Rong Guo, Kai-Yue He, Jia-Li Yuan, et al.Cell|September 6, 2011
BET bromodomain inhibition as a therapeutic strategy to target c-MycJake E Delmore, Ghayas C Issa, Madeleine E Lemieux, et al.Cancer Discovery|November 21, 2019
<i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i>-Mutant Lung AdenocarcinomaFei Li, Qingyuan Huang, Troy A Luster, et al.Theranostics|January 2, 2015
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferonFeng-Qin Hou, Liu-Wei Song, Quan Yuan, et al.Cancer Cell|August 4, 2023
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancerFernando J de Miguel, Claudia Gentile, William W Feng, et al.The Prostate|September 17, 2013
Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese menRong Na, Fang Liu, Penyin Zhang, et al.Cancer Research|July 11, 2020
Epigenetic CRISPR Screens Identify <i>Npm1</i> as a Therapeutic Vulnerability in Non-Small Cell Lung CancerFei Li, Wai-Lung Ng, Troy A Luster, et al.Cell|December 19, 2017
R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m<sup>6</sup>A/MYC/CEBPA SignalingRui Su, Lei Dong, Chenying Li, et al.ACS Chemical Biology|August 14, 2018
Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and BromodomainsJinhua Wang, Tatiana Erazo, Fleur M Ferguson, et al.Pageof 136